The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Effect of KRAS and NRAS mutations on treatment outcomes in patients with metastatic colorectal cancer (mCRC) treated first-line with cetuximab plus FOLFOX4: New results from the OPUS study.
Sabine Tejpar
Consultant or Advisory Role - Merck Serono
Honoraria - Merck Serono
Heinz-Josef Lenz
Consultant or Advisory Role - EMA
Honoraria - Bayer; Bristol-Myers Squibb; Merck; Roche
Claus-Henning Köhne
Consultant or Advisory Role - EMA
Honoraria - Bayer; Bristol-Myers Squibb; Merck KGaA; Roche
Volker Heinemann
Consultant or Advisory Role - Amgen; Merck KGaA; Roche; Sanofi
Honoraria - Amgen; Merck KGaA; Roche; Sanofi
Research Funding - Amgen; Merck KGaA; Roche; Sanofi
Fortunato Ciardiello
Honoraria - Bayer; Merck Serono
Research Funding - AstraZeneca; Bayer; Merck Serono
Regina Esser
Employment or Leadership Position - Merck KGaA
Stock Ownership - Merck KGaA
Frank Beier
Employment or Leadership Position - Merck KGaA
Christopher Stroh
Employment or Leadership Position - Merck Serono
Klaus Duecker
Employment or Leadership Position - Merck Serono
Other Remuneration - Merck Serono
Carsten Bokemeyer
Consultant or Advisory Role - Merck Serono
Honoraria - Merck Serono